Illumina Ventures has led a series A round for SerImmune, which will use the funding to enhance its immune system mapping platform.
SerImmune, a US-based developer of mapping technology for the immune system based on University of California (UC), Santa Barbara research, has raised $8m in a series A round.
The round was led by Illumina Ventures, an independently-managed venture capital fund backed by genomics company Illumina, and included pharmaceutical company Merck & Co, through an unnamed subsidiary, and undisclosed additional investors.
SerImmune has built a system that can map the human immune system to help with the development of therapeutic…
